Rucaparib camsylate - Generic Drug Details

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

What are the generic sources for rucaparib camsylate and what is the scope of patent protection?

Rucaparib camsylate is the generic ingredient in one branded drug marketed by Clovis Oncology Inc and is included in one NDA. There are twelve patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Rucaparib camsylate has two hundred and seventy-nine patent family members in fifty-three countries.

One supplier is listed for this compound.

Summary for rucaparib camsylate

International Patents:	279
US Patents:	12
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	25
Clinical Trials:	6
Patent Applications:	11
DailyMed Link:	rucaparib camsylate at DailyMed

Recent Clinical Trials for rucaparib camsylate

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Alliance for Clinical Trials in Oncology	Phase 3
National Cancer Institute (NCI)	Phase 3
Clovis Oncology, Inc.	Phase 2

See all rucaparib camsylate clinical trials

Pharmacology for rucaparib camsylate

Drug Class	Poly(ADP-Ribose) Polymerase Inhibitor
Mechanism of Action	Poly(ADP-Ribose) Polymerase Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for rucaparib camsylate

L01XK	Poly (ADP-ribose) polymerase (PARP) inhibitors
L01X	OTHER ANTINEOPLASTIC AGENTS
L01	ANTINEOPLASTIC AGENTS
L	Antineoplastic and immunomodulating agents

US Patents and Regulatory Information for rucaparib camsylate

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Try it Free
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Clovis Oncology Inc	RUBRACA	rucaparib camsylate	TABLET;ORAL	209115-001	Dec 19, 2016		RX	Yes	No	See Plans and Pricing	See Plans and Pricing				See Plans and Pricing
Clovis Oncology Inc	RUBRACA	rucaparib camsylate	TABLET;ORAL	209115-003	May 1, 2017		RX	Yes	No	See Plans and Pricing	See Plans and Pricing				See Plans and Pricing
Clovis Oncology Inc	RUBRACA	rucaparib camsylate	TABLET;ORAL	209115-003	May 1, 2017		RX	Yes	No	See Plans and Pricing	See Plans and Pricing				See Plans and Pricing
Clovis Oncology Inc	RUBRACA	rucaparib camsylate	TABLET;ORAL	209115-003	May 1, 2017		RX	Yes	No	See Plans and Pricing	See Plans and Pricing				See Plans and Pricing
Clovis Oncology Inc	RUBRACA	rucaparib camsylate	TABLET;ORAL	209115-001	Dec 19, 2016		RX	Yes	No	See Plans and Pricing	See Plans and Pricing	Y			See Plans and Pricing
Clovis Oncology Inc	RUBRACA	rucaparib camsylate	TABLET;ORAL	209115-002	Dec 19, 2016		RX	Yes	Yes	See Plans and Pricing	See Plans and Pricing	Y			See Plans and Pricing
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for rucaparib camsylate

Subscribe to access the full database, or Try it Free
Country	Patent Number	Title	Estimated Expiration
Cyprus	1110335		See Plans and Pricing
Argentina	080164	SALES Y POLIMORFOS DE 8-FLUORO-2-{4-[(METILAMINO)METIL]FENIL}-1,3,4,5-TETRAHIDRO-6H-ACEPINO[5,4,3-CD]INDOL-6-ONA	See Plans and Pricing
South Africa	200507097	Phthalazinone derivatives	See Plans and Pricing
Slovenia	1660095		See Plans and Pricing
Eurasian Patent Organization	009469	ПРОИЗВОДНЫЕ ФТАЛАЗИНОНА (PHTHALAZINONE DERIVATIVES)	See Plans and Pricing
Russian Federation	2006105652	ТРИЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ ПАРП	See Plans and Pricing
>Country	>Patent Number	>Title	>Estimated Expiration

Supplementary Protection Certificates for rucaparib camsylate

Subscribe to access the full database, or Try it Free
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1633724	596	Finland	See Plans and Pricing
1633724	2015/016	Ireland	See Plans and Pricing	PRODUCT NAME: OLAPARIB, AND SALTS AND SOLVATES THEREOF; REGISTRATION NO/DATE: EU/1/14/959/001 20141216
2534153	2018039	Norway	See Plans and Pricing	PRODUCT NAME: RUKAPARIBKAMSYLAT; REG. NO/DATE: EU/1/17/1250 20180531
1633724	15C0022	France	See Plans and Pricing	PRODUCT NAME: OLAPARIB,SELS ET SOLVATES DE CELUI-CI; REGISTRATION NO/DATE: EU 1/14/959 20141218
1633724	CR 2015 00012	Denmark	See Plans and Pricing	PRODUCT NAME: OLAPARIB, OG SALTE OG SOLVATER DERAF; REG. NO/DATE: EU/1/14/959/001 20141216
2534153	300958	Netherlands	See Plans and Pricing	PRODUCT NAME: RUCAPARIB CAMSYLAAT; REGISTRATION NO/DATE: EU/1/17/1250 20180529
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.